576 related articles for article (PubMed ID: 23609751)
1. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
3. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
[TBL] [Abstract][Full Text] [Related]
4. Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression.
Hou R; Jiang L; Liu D; Lin B; Hu Z; Gao J; Zhang D; Zhang S; Iwamori M
Int J Mol Med; 2017 Aug; 40(2):293-302. PubMed ID: 28586014
[TBL] [Abstract][Full Text] [Related]
5. MUC1 is a promising therapeutic target for prostate cancer therapy.
Li Y; Cozzi PJ
Curr Cancer Drug Targets; 2007 May; 7(3):259-71. PubMed ID: 17504123
[TBL] [Abstract][Full Text] [Related]
6. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Wang ZQ; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Bachvarov D
Oncotarget; 2014 Jan; 5(2):544-60. PubMed ID: 24504219
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
9. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
10. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
11. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
12. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
[TBL] [Abstract][Full Text] [Related]
13. Loss of lamin A but not lamin C expression in epithelial ovarian cancer cells is associated with metastasis and poor prognosis.
Gong G; Chen P; Li L; Tan H; Zhou J; Zhou Y; Yang X; Wu X
Pathol Res Pract; 2015 Feb; 211(2):175-82. PubMed ID: 25499720
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.
Qiu JJ; Lin YY; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Gynecol Oncol; 2014 Jul; 134(1):121-8. PubMed ID: 24662839
[TBL] [Abstract][Full Text] [Related]
15. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.
Ricardo S; Marcos-Silva L; Valente C; Coelho R; Gomes R; David L
Virchows Arch; 2016 Jun; 468(6):715-22. PubMed ID: 27003157
[TBL] [Abstract][Full Text] [Related]
16. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
17. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
18. Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.
Huang B; Yin M; Li X; Cao G; Qi J; Lou G; Sheng S; Kou J; Chen K; Yu B
Oncotarget; 2016 May; 7(19):27552-66. PubMed ID: 27050277
[TBL] [Abstract][Full Text] [Related]
19. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
Xie X; Yang M; Ding Y; Yu L; Chen J
Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
[TBL] [Abstract][Full Text] [Related]
20. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]